The Congress organizers are:
- Residual Risk Reduction Initiative (R3i)
- Russian Society of Cardiology
- Federal Almazov North- West Medical Research Centre.
MSDA Congress 2017 was attended by the leading international clinicians and researchers and experts from different cardiology and diabetes disciplines:
- Jean-Charles Fruchart, President of the R3i Foundation;
- Yuji Matsuzawa, President of the International Society of Atherosclerosis;
- Lale Tokgozoglu, President of the European Society of Atherosclerosis.
At the Congress’ opening ceremony, Evgeny Vladimirovich Shlyakhto, Academician of the Russian Academy of Sciences, President of the Russian Society Cardiology, General Director of the Federal Almazov North-West Medical Research Centre welcomed all participants talking about the history and development strategies of the Centre, and its main achievements.
The main congress topics were:
- Metabolic syndrome 2017 — new evidence of old facts;
- Diabetes and cardiovascular risk management
- Lpid-lowering therapy: evolution and revolution.
At scientific symposia, the problems of an integrated approach to the therapy of patients with type 2 diabetes mellitus and the prevention of cardiovascular complications were presented; the actual aspects of diagnostics and therapy of obesity, hypertension and many other issues were considered.
Young doctors and scientists had the opportunity to make their presentations at the poster session.
The winners of the poster session
the first place – Katsutoshi Miyosawa (Japan) — New lipid-lowering agent K-312 increases phosphorylation of AMP-activated protein kinase: a potential mechanism for PCSK9 reduction.
the first place – Toshiaki Takizawa (Japan) — Selective PPAR? Modulator (SPPARM?) (2): Pemafibrate improved nonalcoholic steatohepatitis (NASH) in experiment animal models.
the second place – Evgeny Astashkin (Russia) — Effect of body weight on spontaneous and induced secretion of oxygen radicals by female blood phagocytes after menopause.
the second place – Inna Zorina (Russia) — Contribution of improvement of the hypothalamic signaling to therapeutic effects of metformin in obesity.
the third place – Angela Polyakova (Russia) – Factors of cardiometabolic risk and polymorphic variants of the modifier genes MADD and GLA in hypertrophic cardiomyopathy
the third place – Ma Y (China) – The C (-915) G polymorphism of transforming growth factor beta-1 gene and risk of atrial fibrillation in patients with metabolic syndrome
The sessions of the 12th International Congress “Metabolic Syndrome, Type 2 Diabetes and Atherosclerosis” were accredited in the system of Continuous Medical Education.
